Enhancer methylation dynamics contribute to cancer plasticity and patient mortality

Genome Research

Volumn 26, Issue 5, 2016, Pages 601-611

  Bell, Rachel E ^a   Golan, Tamar ^a   Sheinboim, Danna ^a   Malcov, Hagar ^a   Amar, David ^a   Salamon, Avi ^a   Liron, Tamar ^a   Gelfman, Sahar ^a,b   Gabet, Yankel ^a   Shamir, Ron ^a   Levy, Carmit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MICRORNA; MICRORNA 200A; MICRORNA 200B; MICRORNA 9; RNA;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL PLASTICITY; CHROMATIN; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; CYTL1 GENE; DNA METHYLATION; GENE; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; KIF14 GENE; MALIGNANT TRANSFORMATION; METASTATIC MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION; RNA SEQUENCE; TUMOR MICROENVIRONMENT; ENHANCER REGION; FEMALE; GENETICS; MALE; MELANOMA; METABOLISM; MORTALITY; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA METHYLATION; DNA, NEOPLASM; ENHANCER ELEMENTS, GENETIC; FEMALE; HUMANS; MALE; MELANOMA;

EID: 84964959544     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.197194.115     Document Type: Article

References (59)

1. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X, Schmidl C, Suzuki T. 2014. An atlas of active enhancers across human cell types and tissues. Nature 507: 455-461.
2. Aran D, Hellman A. 2013. DNA methylation of transcriptional enhancers and cancer predisposition. Cell 154: 11.
3. Aran D, Hellman A. 2014. Unmasking risk loci: DNA methylation illuminates the biology of cancer predisposition. Bioessays 36: 184-190.
4. Aran D, Sabato S, Hellman A. 2013. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol 14: R21.
5. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57: 289-300.
6. Bergman Y, Cedar H. 2013. DNA methylation dynamics in health and disease. Nat Struct Mol Biol 20: 274-281.
7. Brabletz T. 2012. To differentiate or not - routes towards metastasis. Nat Rev Cancer 12: 425-436.
8. Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, Bar-Eli M. 2014. Why is melanoma so metastatic? Pigment Cell Melanoma Res 27: 19-36.
9. Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, Oakes C, Zucknick M, Lipka Daniel B, Weischenfeldt J, et al. 2014. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep 8: 798-806.
10. Buecker C, Wysocka J. 2012. Enhancers as information integration hubs in development: lessons from genomics. Trends Genet 28: 276-284.
11. Bulger M, Groudine M. 2011. Functional and mechanistic diversity of distal transcription enhancers. Cell 144: 327-339.
12. Corson TW, Huang A, Tsao M-S, Gallie BL. 2005. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24: 4741-4753.
13. Craene BD, Berx G. 2013. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110.
14. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. 2011. Evaluation of the Infinium Methylation 450K technology. Epigenomics 3: 771-784.
15. Dillon JP, Waring-Green VJ, Taylor AM, Wilson PJ, Birch M, Gartland A, Gallagher JA. 2012. Primary human osteoblast cultures. In Bone research protocols, 2nd ed. (ed. Helfrich MH, Ralston SH), pp. 3-18. Humana Press-Springer, New York.
16. Easwaran H, Tsai H-C, Baylin Stephen B. 2014. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54: 716-727.
17. Ernst J, Kellis M. 2012. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods 9: 215-216.
18. Esteller M. 2007. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16: R50-R59.
19. Franchini D-M, Schmitz K-M, Petersen-Mahrt SK. 2012. 5-Methylcytosine DNA demethylation: more than losing a methyl group. Annu Rev Genet 46: 419-441.
20. Friedl P, Alexander S. 2011. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147: 992-1009.
21. Goding CR, Pei D, Lu X. 2014. Cancer: pathological nuclear reprogramming? Nat Rev Cancer 14: 568-573.
22. Göke J, Jung M, Behrens S, Chavez L, O'Keeffe S, Timmermann B, Lehrach H, Adjaye J, Vingron M. 2011. Combinatorial binding in human and mouse embryonic stem cells identifies conserved enhancers active in early embryonic development. PLoS Comput Biol 7: e1002304.
23. Golan T, Messer AR, Amitai-Lange A, Melamed ZE, Ohana R, Bell RE, Kapitansky O, Lerman G, Greenberger S, Khaled M. 2015. Interactions of melanoma cells with distal keratinocytes trigger metastasis via Notch signaling inhibition of MITF. Mol Cell 59: 664-676.
24. He B, Chen C, Teng L, Tan K. 2014. Global view of enhancer-promoter interactome in human cells. Proc Natl Acad Sci 111: E2191-E2199.
25. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, et al. 2009. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459: 108-112.
26. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. 2013. Super-enhancers in the control of cell identity and disease. Cell 155: 934-947.
27. Holst F, Moelans CB, Filipits M, Singer CF, Simon R, van Diest PJ. 2012. On the evidence for ESR1 amplification in breast cancer. Nat Rev Cancer 12: 149.
28. Hon GC, Rajagopal N, Shen Y, McCleary DF, Yue F, Dang MD, Ren B. 2013. Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat Genet 45: 1198-1206.
29. Jones PA. 2012. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484-492.
30. Korpal M, Lee ES, Hu G, Kang Y. 2008. The miR-200 family inhibits epithelial- mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914.
31. Kwon YJ, Lee SJ, Koh JS, Kim SH, LeeHW, Kang MC, Bae JB, Kim YJ, Park JH. 2012. Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J Thorac Oncol 7: 20-33.
32. Lam MT, Li W, Rosenfeld MG, Glass CK. 2014. Enhancer RNAs and regulated transcriptional programs. Trends Biochem Sci 39: 170-182.
33. Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ. 2013. Software for computing and annotating genomic ranges. PLoS Comput Biol 9: e1003118.
34. Lee WJ, Roberts-Thomson SJ, Holman NA, May FJ, Lehrbach GM, Monteith GR. 2002. Expression of plasma membrane calcium pump isoform mRNAs in breast cancer cell lines. Cell Signal 14: 1015-1022.
35. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S. 2010. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256.
36. Marzese DM, Scolyer RA, Huynh JL, Huang SK, Hirose H, Chong KK, Kiyohara E, Wang J, Kawas NP, Donovan NC. 2014. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet 23: 226-238.
37. Meacham CE, Morrison SJ. 2013. Tumour heterogeneity and cancer cell plasticity. Nature 501: 328-337.
38. Meyers M, Balch C. 1998. Diagnosis and treatment of metastatic melanoma. In Cutaneous melanoma, 3rd ed. (ed. Balch CM, et al.). Quality Medical Publishing, St. Louis, MO.
39. Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS. 2008. Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res 10: R22.
40. Murata Y, Minami Y, Iwakawa R, Yokota J, Usui S, Tsuta K, Shiraishi K, Sakashita S, Satomi K, Iijima T. 2014. ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma. Cancer Sci 105: 490-497.
41. Pletscher-Frankild S, Pallejà A, Tsafou K, Binder JX, Jensen LJ. 2015. DISEASES: text mining and data integration of disease-gene associations. Methods 74: 83-89.
42. Pogribny IP, Beland FA. 2009. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 66: 2249-2261.
43. R Core Team. 2015. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.Rproject.org/.
44. Richardson B. 2003. Impact of aging on DNA methylation. Ageing Res Rev 2: 245-261.
45. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, WongMC, Maddren M, Fang R, Heitner SG, et al. 2013. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 41(D1): D56-D63.
46. Sharif TR, Sharif M. 1999. Overexpression of protein kinase C ϵ in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol 15: 237-243.
47. Stone A, Zotenko E, Locke WJ, Korbie D, Millar EKA, Pidsley R, Stirzaker C, Graham P, Trau M, Musgrove EA, et al. 2015. DNA methylation of oestrogen- regulated enhancers defines endocrine sensitivity in breast cancer. Nat Commun 6: 7758.
48. Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. 2014. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res 24: 1421-1432.
49. Tam WL, Weinberg RA. 2013. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19: 1438-1449.
50. Teng L, He B, Wang J, Tan K. 2015. 4DGenome: a comprehensive database of chromatin interactions. Bioinformatics 31: 2560-2564.
51. Tian Q, Frierson HF, Krystal GW, Moskaluk CA. 1999. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154: 1643-1647.
52. Verras M, Brown J, Li X, Nusse R, Sun Z. 2004. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 64: 8860-8866.
53. Wen M, Wang H, Zhang X, Long J, Lv Z, Kong Q, An Y. 2012. Cytokine-like 1 is involved in the growth and metastasis of neuroblastoma cells. Int J Oncol 41: 1419-1424.
54. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. 2013. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153: 307-319.
55. Wickham H. 2007. Reshaping data with the reshape package. J Stat Softw 21: 1-20.
56. You JS, Jones PA. 2012. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22: 9-20.
57. Zhou VW, Goren A, Bernstein BE. 2011. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12: 7-18.
58. Zhu X-L, Liang L, Ding Y-Q. 2008. Overexpression of FMNL2 is closely related to metastasis of colorectal cancer. Int J Colorectal Dis 23: 1041-1047.
59. Ziller MJ, Gu H, Müller F, Donaghey J, Tsai LT-Y, Kohlbacher O, De Jager PL, Rosen ED, Bennett DA, Bernstein BE. 2013. Charting a dynamic DNA methylation landscape of the human genome. Nature 500: 477-481.